Login
Companies $DNA
$8.50 +$0.00 (0.0%) After hours
Ginkgo Bioworks Holdings, Inc. logo

Ginkgo Bioworks Holdings, Inc.

Compare classes
investors.ginkgobioworks.com

What Do They Do?

Provides cell-engineering research services and tools that help pharmaceutical and biotechnology, agricultural, and industrial customers develop biological products. Also offers governments services to monitor and analyze biological threats.

How Do They Make Money?

Customers pay for cell-engineering research, data packages and lab automation through fixed or cost-based fees, paid upfront or as work proceeds; some agreements also include milestone payments and royalties on customers’ product sales. Biosecurity customers pay fees for data, analysis and services.

revenue
SegmentShareRevenue
Cell Engineering
Mix

78%
FY2022: 30%
Service
22%
FY2022: 63%
Product
0.0%
FY2022: 7.4%

Who Are Their Customers?

Government agencies engage Ginkgo as a prime contractor or R&D subcontractor; pharmaceutical and biotechnology, agriculture, and industrial customers use its cell-engineering services and tools.

Customers above 10% of revenue, FY2025
of revenue from two customers (15%, 12%)
FY2023: 23% from two customers

Do Revenues Turn Into Profits?

No. It lost $312.8M in FY2025.

Operating income, FY2025
−185% of revenue
▲ +44% (Loss) vs FY2024 (−$559.8M, −247%)
Net income, FY2025
−184% of revenue
▲ +43% (Loss) vs FY2024 (−$547M, −241%)
Free cash flow, FY2025
−105% of revenue
▲ +53% (Loss) vs FY2024 (−$382.1M, −168%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −6%
vs $29.4M in Q3 FY2025
Net income
▲ +49% (Loss)
vs −$80.8M in Q3 FY2025
  • Apr 7, 2026 Transferred Biosecurity operations to Tower Biosecurity for shares In exchange, Ginkgo received shares representing approximately 20% of the purchaser’s fully diluted equity.

Shrinking. Revenue fell 46% in 4 years, from $313.8M in FY2021 to $170.2M in FY2025, about 14% a year.

Customer-facing tools The older report describes an end-to-end cell-programming service platform; the latest report adds offerings that let customers run some research in-house and buy lab automation and data-generation services.

Downstream payments The older report described service fees plus customer value sharing through milestones, royalties or equity. The latest says it is moving toward milestones and commercial royalties instead of equity, and has removed downstream value sharing from some program types.

Biosecurity services The older report described biosecurity infrastructure in development; the latest names Canopy for biomonitoring and Horizon for digital threat surveillance.

Revenue over time
Cell Engineering Service Product
$500M$250M$0

Who Do They Compete With?

Competes with AbCellera, Codexis, Senti Bio, WuXi Biologics, Evotec, Charles River Laboratories, HighRes Biosolutions, Automata, Thermo Fisher Scientific, Verily, Biobot, BlueDot, Airfinity, Public Health, and BGI

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support